FDA grants full ap­proval to Leqem­bi, open­ing up cov­er­age of Alzheimer’s drug by Medicare

For the first time in 20 years, the FDA has be­stowed full ap­proval on a drug to treat Alzheimer’s dis­ease, open­ing the door to cov­er­age for mil­lions of Medicare re­cip­i­ents.

While Ei­sai and Bio­gen’s drug Leqem­bi had been avail­able since Jan­u­ary af­ter the FDA cleared it through the ac­cel­er­at­ed ap­proval path­way, the lack of re­im­burse­ment from Medicare had been a ma­jor bar­ri­er for its up­take.

“To­day is a tri­umph for the Alzheimer’s dis­ease com­mu­ni­ty af­ter so many years of hard work by sci­en­tists, clin­i­cians, and clin­i­cal tri­al par­tic­i­pants,” Ei­sai’s US chair­man and CEO Ivan Che­ung told End­points News in an in­ter­view. “This is a very hum­bling mo­ment. I per­son­al­ly wish this would have come many years ear­li­er.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER